AbelZeta Pharma

AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, December 27, 2023 – AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced that Tony (Bizuo) Liu, Chairman and CEO, will present an update on the Company at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.

Live Presentation: January 10, 2024
Time: 8:00-8:25am PT
Location: Mission Bay (32nd Floor) The Westin, San Francisco

About AbelZeta Pharma, Inc.

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body’s own immune system to fight against hematological malignancies, inflammatory and immunological diseases and solid tumors. AbelZeta advances research and development in its own GMP facilities at its centers of excellence, with a pipeline comprised of multiple CAR-T therapies.

Forward-Looking Statements

Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to numerous factors. Forward looking statements are based on the current beliefs and management’s expectations and are subject to significant risks and uncertainties outside of AbelZeta Pharma, Inc.’s (“AbelZeta” or the “Company”) control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, AbelZeta does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Company Contact:

Sarah Kelly
Director of Communications
AbelZeta Pharma Inc.
Phone: +1 (240) 552 5870
Email: [email protected]

Scroll to Top